This study evaluates how often women with throat (oropharyngeal) cancer or who have a partner with oropharyngeal cancer get anogenital infections with high risk, potentially cancer-causing types of human papilloma virus (HPV).
* Female patients with diagnosed HPV(+)OPSCC seen at the Mayo Clinic, Rochester
Age ≥ 18
Female partners of Mayo Clinic patients with diagnosed HPV(+)OPSCC
Patient has given permission to give his/her blood/saliva sample for research testing
* HPV(-) OPSCC
Unable to provide informed consent
Unwilling to attend screening visit at Mayo Clinic site, if indicated
Unwilling/unable to complete surveys electronically
Female patients and female partners of patients with confirmed HPV associated oropharyngeal carcinoma (PAP-OP)
Cohort
Prospective
Non-Interventional Study
Other interventionNon-interventional study
Incidence and prevalence of HPV(+) associated anogenital pathology in patients with newly diagnosed HPV(+)OPSCC
Prevalence and incidence of human papilloma virus (HPV)-related anogenital disease in female patients with HPV-mediated oropharyngeal squamous cell carcinoma (HPV(+)OPSCC) will be compared to a population of patients with similar demographic and comorbidity status. Rates will be compared across groups using tests for proportional variables (Fisher's exact, Chi Square).
Incidence and prevalence of HPV(+) associated anogenital pathology in partners of patients with newly diagnosed HPV(+)OPSCC
Prevalence and incidence of human papilloma virus (HPV)-related anogenital disease in female partners of HPV-mediated oropharyngeal squamous cell carcinoma (HPV(+)OPSCC) patients will be compared to a population of patients with similar demographic and comorbidity status. Rates will be compared across groups using tests for proportional variables (Fisher's exact, Chi Square).
Click on the lead sponsor to view all of their trials.
